Avalo Therapeutics Inc (AVTX) - Total Liabilities
Based on the latest financial reports, Avalo Therapeutics Inc (AVTX) has total liabilities worth $33.55 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Avalo Therapeutics Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Avalo Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See AVTX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Avalo Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Avalo Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Hile Bio-tech
SHG:603718
|
China | CN¥312.90 Million |
|
Nerdwallet Inc
NASDAQ:NRDS
|
USA | $95.80 Million |
|
Wanxiang Doneed Co Ltd
SHG:600371
|
China | CN¥126.60 Million |
|
JNK India Ltd
NSE:JNKINDIA
|
India | Rs4.91 Billion |
|
First Western Financial Inc
NASDAQ:MYFW
|
USA | $2.97 Billion |
|
Lingnan Landscape Co Ltd
SHE:002717
|
China | CN¥12.61 Billion |
|
Samyang Cor
KO:145990
|
Korea | ₩1.84 Trillion |
|
Brooge Holdings Ltd
NASDAQ:BROG
|
USA | $429.22 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Avalo Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Avalo Therapeutics Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avalo Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avalo Therapeutics Inc (2012–2024)
The table below shows the annual total liabilities of Avalo Therapeutics Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.70 Million | +29.30% |
| 2023-12-31 | $13.69 Million | -69.09% |
| 2022-12-31 | $44.28 Million | -22.49% |
| 2021-12-31 | $57.13 Million | +197.67% |
| 2020-12-31 | $19.19 Million | +26.99% |
| 2019-12-31 | $15.11 Million | -69.37% |
| 2018-12-31 | $49.34 Million | +223.25% |
| 2017-12-31 | $15.26 Million | +174.44% |
| 2016-12-31 | $5.56 Million | -35.13% |
| 2015-12-31 | $8.57 Million | -77.81% |
| 2014-12-31 | $38.65 Million | +68.60% |
| 2013-12-31 | $22.92 Million | +1384.80% |
| 2012-12-31 | $1.54 Million | -- |
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more